MA41346A - Eléments régulateurs post-transcriptionnels d'hépatite modifiée - Google Patents
Eléments régulateurs post-transcriptionnels d'hépatite modifiéeInfo
- Publication number
- MA41346A MA41346A MA041346A MA41346A MA41346A MA 41346 A MA41346 A MA 41346A MA 041346 A MA041346 A MA 041346A MA 41346 A MA41346 A MA 41346A MA 41346 A MA41346 A MA 41346A
- Authority
- MA
- Morocco
- Prior art keywords
- post
- regulatory elements
- transcriptional regulatory
- modified hepatitis
- hepatitis
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000001124 posttranscriptional effect Effects 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10041—Use of virus, viral particle or viral elements as a vector
- C12N2730/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562102569P | 2015-01-12 | 2015-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41346A true MA41346A (fr) | 2017-11-21 |
Family
ID=55310922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041346A MA41346A (fr) | 2015-01-12 | 2016-01-11 | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10363269B2 (fr) |
| EP (1) | EP3245292B1 (fr) |
| JP (1) | JP6868560B2 (fr) |
| KR (1) | KR102554374B1 (fr) |
| CN (1) | CN107429260B (fr) |
| AU (1) | AU2016206868B2 (fr) |
| BR (1) | BR112017014917A2 (fr) |
| CA (1) | CA2973483A1 (fr) |
| ES (1) | ES2877367T3 (fr) |
| IL (1) | IL253399B2 (fr) |
| MA (1) | MA41346A (fr) |
| MX (1) | MX391694B (fr) |
| MY (1) | MY187559A (fr) |
| RU (1) | RU2734594C2 (fr) |
| SA (1) | SA517381912B1 (fr) |
| SG (1) | SG11201705692SA (fr) |
| WO (1) | WO2016115177A1 (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215601B1 (fr) | 2014-11-05 | 2020-05-27 | Juno Therapeutics, Inc. | Procédés de transduction et de traitement de cellules |
| CN108350062B (zh) | 2015-08-06 | 2022-10-14 | 达纳-法伯癌症研究所股份有限公司 | 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应 |
| KR102673203B1 (ko) | 2016-04-20 | 2024-06-10 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | Pklr의 유전자 발현 증강을 위한 조성물 및 방법 |
| MX2019004487A (es) | 2016-10-20 | 2020-02-07 | Sangamo Therapeutics Inc | Metodos y composiciones para el tratamiento de la enfermedad de fabry. |
| CN107058315B (zh) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| WO2018148440A1 (fr) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Régulation de récepteurs d'antigènes chimériques |
| WO2019028273A1 (fr) * | 2017-08-02 | 2019-02-07 | Dna2.0, Inc. Dba Atum | Vecteurs d'adn et éléments pour l'expression génique soutenue dans des cellules eucaryotes |
| CA3076337A1 (fr) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions pour la therapie par lymphocytes t a recepteur antigenique chimerique et leurs utilisations |
| CN119345398A (zh) | 2017-10-16 | 2025-01-24 | 能源环境和技术研究中心O.A.,M.P. | 用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体 |
| AU2019261646A1 (en) | 2018-04-27 | 2020-11-12 | Spacecraft Seven, Llc | Gene therapy for CNS degeneration |
| CA3113618A1 (fr) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Molecules immunomodulatrices localisees dans le collagene et leurs procedes |
| EA202192738A1 (ru) | 2019-04-12 | 2022-03-17 | С4 Терапьютикс, Инк. | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
| CN111825769B (zh) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | 一种泛素化缺失的嵌合抗原受体及其用途 |
| AR119271A1 (es) | 2019-06-11 | 2021-12-09 | Shire Human Genetic Therapies | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada |
| EP3990491A1 (fr) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Complexes protéine de fusion-hydroxyde métallique immunomodulateurs et leurs procédés |
| WO2021061648A1 (fr) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Méthodes et compositions pour la stimulation de réponses de lymphocytes t endogènes |
| JP7659550B2 (ja) | 2019-10-23 | 2025-04-09 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療 |
| IL296242A (en) | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Methods for producing engineered memory-like nk cells and preparations containing them |
| JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| AU2021265083A1 (en) | 2020-04-27 | 2022-12-15 | Juno Therapeutics, Inc. | Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity |
| WO2021221782A1 (fr) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Ligands chimériques ciblant des récepteurs antigéniques et leurs utilisations |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021252952A1 (fr) * | 2020-06-11 | 2021-12-16 | Sangamo Therapeutics, Inc. | Procédés et compositions pour l'expression de phénylalanine hydroxylase |
| IL299414A (en) * | 2020-06-30 | 2023-02-01 | Univ Court Univ Of Edinburgh | Transgene expression system |
| AU2021320902A1 (en) | 2020-08-07 | 2023-04-06 | Spacecraft Seven, Llc | Plakophilin-2 (PKP2) gene therapy using AAV vector |
| KR20220035693A (ko) * | 2020-09-14 | 2022-03-22 | 주식회사 제너로스 | 표적화된 유전자 전달을 위한 아데노-부속 바이러스 벡터 |
| PH12023550859A1 (en) * | 2020-09-29 | 2023-11-20 | Neuexcell Therapeutics Inc | Dlx2 vector |
| EP4263614A1 (fr) | 2020-12-16 | 2023-10-25 | Takeda Pharmaceutical Company Limited | Administration d'anticorps à l'aide de vecteurs viraux adéno-associés pour le traitement d'une maladie médiée par une kallicréine plasmatique dérégulée |
| UY39772A (es) * | 2021-05-21 | 2023-01-31 | Novartis Ag | Composiciones y métodos para mejorar la función visual |
| WO2023081715A1 (fr) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Association d'une thérapie de lymphocytes car t avec des inhibiteurs de tyrosine kinase de bruton et procédés d'utilisation associés |
| CA3236331A1 (fr) * | 2021-11-04 | 2023-05-11 | Mayo Foundation For Medical Education And Research | Methodes et materiels pour le traitement du cancer |
| AU2023304369A1 (en) | 2022-07-07 | 2025-01-16 | Science Corporation | Neural interface device |
| EP4598572A1 (fr) * | 2022-10-04 | 2025-08-13 | Emergent Product Development Gaithersburg Inc. | Nouvelles formulations de virus vsv |
| WO2024226858A1 (fr) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Procédés de fabrication de vecteurs viraux |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| EP0452342B1 (fr) | 1988-12-28 | 1994-11-30 | MILTENYI, Stefan | Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| JP3150340B2 (ja) | 1990-11-13 | 2001-03-26 | イムネクス コーポレイション | 二機能選択可能融合遺伝子 |
| JPH09500783A (ja) | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997034634A1 (fr) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| WO2000014257A1 (fr) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7262049B2 (en) | 1999-03-16 | 2007-08-28 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
| AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2344208A1 (fr) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Methode |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7384738B2 (en) | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| DK2856876T3 (en) | 2007-03-30 | 2018-04-03 | Memorial Sloan Kettering Cancer Center | Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes |
| EP2520643B8 (fr) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Systèmes de traitement d'échantillons et procédés |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| EP2814846B1 (fr) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
| WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
| JP6251734B2 (ja) | 2012-05-03 | 2017-12-27 | フレッド ハッチンソン キャンサー リサーチ センター | 親和性増強型ｔ細胞受容体およびその作製方法 |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| MX378463B (es) | 2013-02-26 | 2025-03-10 | Memorial Sloan Kettering Cancer Center | Composiciones y usos de las mismas para inmunoterapia. |
| CA3185368A1 (fr) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Generation efficace de lymphocytes t ciblant une tumeur derives de cellules souches pluripotentes |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| US10494434B2 (en) | 2013-12-20 | 2019-12-03 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| KR102463529B1 (ko) | 2014-04-10 | 2022-11-07 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 약물 관련 트랜스진 발현 |
| KR20160002030A (ko) * | 2014-06-30 | 2016-01-07 | 성지산업 주식회사 | 도플러 센서를 이용한 대상체 감지 방법 및 장치 |
| EP3215601B1 (fr) | 2014-11-05 | 2020-05-27 | Juno Therapeutics, Inc. | Procédés de transduction et de traitement de cellules |
-
2016
- 2016-01-11 MA MA041346A patent/MA41346A/fr unknown
- 2016-01-12 MY MYPI2017001032A patent/MY187559A/en unknown
- 2016-01-12 AU AU2016206868A patent/AU2016206868B2/en active Active
- 2016-01-12 KR KR1020177022738A patent/KR102554374B1/ko active Active
- 2016-01-12 MX MX2017009113A patent/MX391694B/es unknown
- 2016-01-12 WO PCT/US2016/013109 patent/WO2016115177A1/fr not_active Ceased
- 2016-01-12 EP EP16703392.7A patent/EP3245292B1/fr active Active
- 2016-01-12 CN CN201680015106.6A patent/CN107429260B/zh active Active
- 2016-01-12 ES ES16703392T patent/ES2877367T3/es active Active
- 2016-01-12 SG SG11201705692SA patent/SG11201705692SA/en unknown
- 2016-01-12 US US14/994,114 patent/US10363269B2/en active Active
- 2016-01-12 RU RU2017126975A patent/RU2734594C2/ru active
- 2016-01-12 CA CA2973483A patent/CA2973483A1/fr active Pending
- 2016-01-12 JP JP2017536779A patent/JP6868560B2/ja active Active
- 2016-01-12 BR BR112017014917A patent/BR112017014917A2/pt not_active Application Discontinuation
-
2017
- 2017-07-10 IL IL253399A patent/IL253399B2/en unknown
- 2017-07-12 SA SA517381912A patent/SA517381912B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY187559A (en) | 2021-09-29 |
| WO2016115177A1 (fr) | 2016-07-21 |
| BR112017014917A2 (pt) | 2018-03-13 |
| US20160199412A1 (en) | 2016-07-14 |
| EP3245292B1 (fr) | 2021-06-09 |
| JP2018502583A (ja) | 2018-02-01 |
| MX391694B (es) | 2025-03-21 |
| SA517381912B1 (ar) | 2021-12-30 |
| CA2973483A1 (fr) | 2016-07-21 |
| JP6868560B2 (ja) | 2021-05-12 |
| CN107429260A (zh) | 2017-12-01 |
| KR102554374B1 (ko) | 2023-07-11 |
| ES2877367T3 (es) | 2021-11-16 |
| AU2016206868B2 (en) | 2022-03-17 |
| SG11201705692SA (en) | 2017-08-30 |
| HK1246347A1 (en) | 2018-09-07 |
| RU2734594C2 (ru) | 2020-10-20 |
| MX2017009113A (es) | 2017-11-15 |
| AU2016206868A1 (en) | 2017-07-27 |
| US10363269B2 (en) | 2019-07-30 |
| EP3245292A1 (fr) | 2017-11-22 |
| IL253399B2 (en) | 2023-06-01 |
| RU2017126975A3 (fr) | 2019-09-04 |
| KR20170131362A (ko) | 2017-11-29 |
| CN107429260B (zh) | 2021-12-31 |
| IL253399A0 (en) | 2017-09-28 |
| RU2017126975A (ru) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41346A (fr) | Eléments régulateurs post-transcriptionnels d'hépatite modifiée | |
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| DK3805376T3 (da) | Modificeret virus | |
| EP3360554A4 (fr) | Agent anti-virus de l'hépatite b | |
| DK3565568T3 (da) | Ændret virus | |
| LT3320033T (lt) | Polietileno tereftalato depolimerizacija | |
| DK3302565T3 (da) | Faste doseringsformer af palbociclib | |
| HUE042693T2 (hu) | Kapszid | |
| DK3354729T3 (da) | Anti-garp-antistof | |
| DK3209698T4 (da) | Transgene mus | |
| EP3967832C0 (fr) | Enceinte pliante | |
| EP3341259A4 (fr) | Brouette | |
| PL3457851T3 (pl) | Pochodne sobetiromu | |
| PL3261437T3 (pl) | Grzybobójcze związki i kompozycje | |
| EP3302376A4 (fr) | Dilatateurs nasaux | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| EP3341117C0 (fr) | Réacteur | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| IL246509A0 (en) | Coordinating multiple components | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3201323T3 (da) | Modificering af bakteriofag | |
| EP3384016A4 (fr) | Phagémides modifiés | |
| DK3263590T3 (da) | Fiskevirus | |
| EP3467158A4 (fr) | Creuset |